JP2022514219A5 - - Google Patents

Info

Publication number
JP2022514219A5
JP2022514219A5 JP2021532865A JP2021532865A JP2022514219A5 JP 2022514219 A5 JP2022514219 A5 JP 2022514219A5 JP 2021532865 A JP2021532865 A JP 2021532865A JP 2021532865 A JP2021532865 A JP 2021532865A JP 2022514219 A5 JP2022514219 A5 JP 2022514219A5
Authority
JP
Japan
Prior art keywords
cancer
cells
item
composition according
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021532865A
Other languages
English (en)
Japanese (ja)
Other versions
JP7813453B2 (ja
JP2022514219A (ja
Filing date
Publication date
Priority claimed from KR1020180158428A external-priority patent/KR20200071198A/ko
Application filed filed Critical
Publication of JP2022514219A publication Critical patent/JP2022514219A/ja
Publication of JP2022514219A5 publication Critical patent/JP2022514219A5/ja
Priority to JP2025148485A priority Critical patent/JP2025175073A/ja
Application granted granted Critical
Publication of JP7813453B2 publication Critical patent/JP7813453B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021532865A 2018-12-10 2019-12-09 Nrf-2欠損細胞及びその使用 Active JP7813453B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025148485A JP2025175073A (ja) 2018-12-10 2025-09-08 Nrf-2欠損細胞及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020180158428A KR20200071198A (ko) 2018-12-10 2018-12-10 Nrf2 발현 조절 기반 T 세포 항암면역치료법
KR10-2018-0158428 2018-12-10
PCT/US2019/065227 WO2020123377A1 (en) 2018-12-10 2019-12-09 Nrf-2 deficient cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025148485A Division JP2025175073A (ja) 2018-12-10 2025-09-08 Nrf-2欠損細胞及びその使用

Publications (3)

Publication Number Publication Date
JP2022514219A JP2022514219A (ja) 2022-02-10
JP2022514219A5 true JP2022514219A5 (cg-RX-API-DMAC7.html) 2022-12-19
JP7813453B2 JP7813453B2 (ja) 2026-02-13

Family

ID=69187892

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532865A Active JP7813453B2 (ja) 2018-12-10 2019-12-09 Nrf-2欠損細胞及びその使用
JP2025148485A Pending JP2025175073A (ja) 2018-12-10 2025-09-08 Nrf-2欠損細胞及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025148485A Pending JP2025175073A (ja) 2018-12-10 2025-09-08 Nrf-2欠損細胞及びその使用

Country Status (8)

Country Link
US (1) US12655425B2 (cg-RX-API-DMAC7.html)
EP (1) EP3893900B1 (cg-RX-API-DMAC7.html)
JP (2) JP7813453B2 (cg-RX-API-DMAC7.html)
KR (2) KR20200071198A (cg-RX-API-DMAC7.html)
CN (1) CN113395973A (cg-RX-API-DMAC7.html)
AU (1) AU2019398111B2 (cg-RX-API-DMAC7.html)
CA (1) CA3122096A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020123377A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
WO2021127392A1 (en) * 2019-12-19 2021-06-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Systems and methods for predicting individual patient response to radiotherapy using a dynamic carrying capacity model

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
WO1998014179A1 (en) 1996-10-01 1998-04-09 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
GB9622500D0 (en) 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US8202846B2 (en) 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
JP2003526367A (ja) 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Rna干渉の方法とrna干渉組成物
ATE347593T1 (de) 2002-01-23 2006-12-15 Univ Utah Res Found Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
US8206965B2 (en) 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
EP1504092B2 (en) 2002-03-21 2014-06-25 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US9447434B2 (en) 2002-09-05 2016-09-20 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
AU2003290518A1 (en) 2002-09-06 2004-04-23 Fred Hutchinson Cancer Research Center Methods and compositions concerning designed highly-specific nucleic acid binding proteins
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP1591521A1 (en) 2004-04-30 2005-11-02 Cellectis I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
KR20070060115A (ko) 2004-09-16 2007-06-12 상가모 바이오사이언스 인코포레이티드 단백질 생산을 위한 조성물 및 방법
ATE466933T1 (de) 2005-03-15 2010-05-15 Cellectis I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
US7812002B2 (en) 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
CA2871042A1 (en) 2012-04-20 2013-10-24 The Sun Products Corporation Liquid detergent compositions
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
EP4397759A3 (en) 2012-10-23 2024-10-09 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
DK3363902T3 (da) 2012-12-06 2020-01-02 Sigma Aldrich Co Llc Crispr-baseret genommodifikation og -regulering
SG10201707569YA (en) 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
IL308158A (en) 2012-12-17 2023-12-01 Harvard College Rna-guided human genome engineering
WO2014131833A1 (en) 2013-02-27 2014-09-04 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Gene editing in the oocyte by cas9 nucleases
WO2015191693A2 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
CN104877967A (zh) 2015-05-26 2015-09-02 中山大学附属第三医院 一种过表达Nrf2基因的细胞株MSCs及其制备方法及应用
WO2019165067A1 (en) 2018-02-21 2019-08-29 Bristol-Myers Squibb Company Camk2d antisense oligonucleotides and uses thereof
EP3830114A4 (en) 2018-07-31 2022-08-03 Washington University USE OF INTERLEUKIN-7 AND CHIMERA ANTIGEN RECEPTOR (CAR) IMMUNE EFFECTOR CELLS FOR TUMOR TREATMENT
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법

Similar Documents

Publication Publication Date Title
JP7748431B2 (ja) FcイプシロンCAR
JP7719128B2 (ja) 治療免疫細胞の有効性を改良するための方法
Jogalekar et al. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments
Saeed et al. Engineering nanoparticles to reprogram the tumor immune microenvironment for improved cancer immunotherapy
Musetti et al. Nanoparticle-mediated remodeling of the tumor microenvironment to enhance immunotherapy
Li et al. CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety
Sangiolo Cytokine induced killer cells as promising immunotherapy for solid tumors
JP2018510881A5 (cg-RX-API-DMAC7.html)
JP7837068B2 (ja) ユニバーサル抗原提示細胞およびその使用
CA3071282A1 (en) T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
JP2018533625A5 (cg-RX-API-DMAC7.html)
KR20190039597A (ko) 세포 치료요법을 위한 항상성 활성 사이토킨 수용체
KR20220035910A (ko) Car-t 세포의 인시츄 모집, 재프로그래밍 및 방출
US20190040392A1 (en) Targeted mrna for in vivo application
Li et al. Adoptive cell immunotherapy for breast cancer: harnessing the power of immune cells
Wang et al. Prospects for γδ T cells and chimeric antigen receptor γδ T cells in cancer immunotherapy
Lin et al. Synthetic cells and molecules in cellular immunotherapy
JP2021525067A5 (cg-RX-API-DMAC7.html)
Santerre et al. Biomaterials’ enhancement of immunotherapy for breast cancer by targeting functional cells in the tumor micro-environment
Wang et al. Advanced strategies in improving the immunotherapeutic effect of CAR‐T cell therapy
JP2021517454A5 (cg-RX-API-DMAC7.html)
Zhang et al. CAR‐DC combined with CAR‐T therapy for relapsed/refractory acute myeloid leukaemia: Research progress and future perspectives
Mohammadkhani et al. Memory programming and new manufacturing paradigms in CAR-T cell therapy
EP4279085A1 (en) Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
Ali et al. Is Adoptive Cellular Therapy With Non–T-Cell Immune Effectors the Future?